

DxWound Genetic Analysis Report Bibliography

1. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013. <https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf>. Accessed April 17, 2017.
2. CLSI. *Performance Standards for Antimicrobial Testing*. 27th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.
3. Arthur M, Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. *Antimicrob Agents Chemother*. 1993;37(8):1563-1571.
4. Bush K, Jacoby GA. Updated functional classification of beta-lactamases. *Antimicrob Agents Chemother*. 2010;54(3):969-976.
5. Clark NC, Cooksey RC, Hill BC, Swenson JM, Tenover FC. Characterization of glycopeptide-resistant enterococci from U.S. hospitals. *Antimicrob Agents Chemother*. 1993;37(11):2311-2317.
6. Fyfe C, Grossman TH, Kerstein K, Sutcliffe J. Resistance to Macrolide Antibiotics in Public Health Pathogens. *Cold Spring Harb Perspect Med*. 2016;6(10).
7. Gordon RJ, Lowy FD. Pathogenesis of methicillin-resistant *Staphylococcus aureus* infection. *Clin Infect Dis*. 2008;46 Suppl 5:S350-359.
8. Hussain Z, Stoakes L, Massey V, et al. Correlation of oxacillin MIC with *mecA* gene carriage in coagulase-negative staphylococci. *Journal of clinical microbiology*. 2000;38(2):752-754.
9. Isogai N, Urushibara N, Kawaguchiya M, et al. Characterization of *Enterococcus faecium* with macrolide resistance and reduced susceptibility to quinupristin/dalfopristin in a Japanese hospital: detection of extensive diversity in *erm(B)*-regulator regions. *Microb Drug Resist*. 2013;19(4):298-307.
10. Lim JA, Kwon AR, Kim SK, Chong Y, Lee K, Choi EC. Prevalence of resistance to macrolide, lincosamide and streptogramin antibiotics in Gram-positive cocci isolated in a Korean hospital. *J Antimicrob Chemother*. 2002;49(3):489-495.
11. Peacock SJ, Paterson GK. Mechanisms of Methicillin Resistance in *Staphylococcus aureus*. *Annu Rev Biochem*. 2015;84:577-601.
12. Perichon B, Courvalin P. VanA-type vancomycin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother*. 2009;53(11):4580-4587.
13. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. *Clinical microbiology reviews*. 2007;20(3):440-458, table of contents.
14. Roberts MC, Sutcliffe J, Courvalin P, Jensen LB, Rood J, Seppala H. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. *Antimicrob Agents Chemother*. 1999;43(12):2823-2830.
15. Roberts MC. Update on macrolide-lincosamide-streptogramin, ketolide, and oxazolidinone resistance genes. *FEMS Microbiol Lett*. 2008;282(2):147-159.
16. Shallcross LJ, Fragaszy E, Johnson AM, Hayward AC. The role of the Panton-Valentine leucocidin toxin in staphylococcal disease: a systematic review and meta-analysis. *Lancet Infect Dis*. 2013;13(1):43-54.
17. Wisplinghoff H, Rosato AE, Enright MC, Noto M, Craig W, Archer GL. Related clones containing SCCmec type IV predominate among clinically significant *Staphylococcus epidermidis* isolates. *Antimicrob Agents Chemother*. 2003;47(11):3574-3579.



Contact CogenDx to learn more.

Client Services: **877.866.0603**

www.cogendx.com